Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor–Positive, <i>ERBB2</i>–Negative Metastatic Breast Cancer
In this cohort study, the duration of tumor control achieved with CDK4/6i-based therapy and the presence of visceral metastases emerged as key factors that may affect treatment decision. Oral CT may offer potential benefits for specific patient subgroups.
Authors
- Carmen Criscitiello (ORCID: https://orcid.org/0000-0001-9064-0113)
- Giuseppe Curigliano (ORCID: https://orcid.org/0000-0003-1781-2518)
- Paola Zagami (ORCID: https://orcid.org/0000-0002-2687-6436)
- Claudio Vernieri (ORCID: https://orcid.org/0000-0003-1577-8176)
- Sara Gandini (ORCID: https://orcid.org/0000-0002-1348-4548)
- Eleonora Nicolò (ORCID: https://orcid.org/0000-0001-5042-6550)
- Pier Paolo Maria Berton Giachetti (ORCID: https://orcid.org/0000-0001-5559-7279)
- Emma Zattarin (ORCID: https://orcid.org/0000-0002-3445-9245)
- Fabiola Giudici (ORCID: https://orcid.org/0000-0002-4160-3479)
- Chiara Corti (ORCID: https://orcid.org/0000-0002-0359-0267)
- Beatrice Taurelli Salimbeni (ORCID: https://orcid.org/0000-0002-7345-4148)
- Michelino De Laurentiis (ORCID: https://orcid.org/0000-0001-9009-1572)
- Andrea Botticelli (ORCID: https://orcid.org/0000-0002-6425-9893)
- Carmine De Angelis (ORCID: https://orcid.org/0000-0003-1158-4630)
- Dario Trapani (ORCID: https://orcid.org/0000-0003-1672-9560)
- Simone Scagnoli (ORCID: https://orcid.org/0000-0003-4943-5622)
- Elisabetta Munzone (ORCID: https://orcid.org/0000-0003-3371-3878)
- Ambra Carnevale Schianca
- Giampaolo Bianchini (ORCID: https://orcid.org/0000-0002-6790-6267)
- Annarita Verrazzo (ORCID: https://orcid.org/0009-0007-0974-3635)
- Stefania Morganti (ORCID: https://orcid.org/0000-0001-5284-9944)
- Caterina Sposetti (ORCID: https://orcid.org/0000-0003-3211-8516)
- Mario Giuliano (ORCID: https://orcid.org/0000-0003-0835-3153)
- Giulia Viale (ORCID: https://orcid.org/0000-0001-7280-361X)
- Roberta Scafetta
- Matteo Lambertini (ORCID: https://orcid.org/0000-0003-1797-5296)
- Maria Grazia Razeti
- Antonio Marra (ORCID: https://orcid.org/0000-0002-7310-7824)
- Laura Boldrini (ORCID: https://orcid.org/0009-0006-0607-2154)
- Angela Espósito
- Bianca Malagutti
- Roberta Caputo (ORCID: https://orcid.org/0000-0003-4231-1184)
Institutions
- Broad Institute (US)
- Harvard University (US)
- Vita-Salute San Raffaele University (IT)
- University of Milan (IT)
- Cornell University (US)
- Azienda Ospedaliero-Universitaria di Modena (IT)
- IFOM (IT)
- Federico II University Hospital (IT)
- Dana-Farber Cancer Institute (US)
- Centro di Riferimento Oncologico (IT)
- IRCCS Ospedale San Raffaele (IT)
- Campus Bio Medico University Hospital (IT)
- Ospedale Policlinico San Martino (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Weill Cornell Medicine (US)
- European Institute of Oncology (IT)
- University of Genoa (IT)
- Sapienza University of Rome (IT)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2025-02-21
- DOI
- https://doi.org/10.1001/jamanetworkopen.2024.61067
- Citations
- 8
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 12.15